Q2 sales rise 8.8%, but consolidated loss and subsidiary risks persist

Going ConcernEmphasis Of MatterEbitda Margin CompressionPat NegativeResults RestatedExceptional ItemResults View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹272.70

prior close

₹269.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.7%-0.2% vs market

Pharmaceuticals peers, median of 156sector-1.1%-0.8% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+1.0

15m

+1.1

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.9-1.7-0.2-1.1-0.8

Next day

-4.5-1.3-3.2-1.4-3.1

-2.6-1.7-1.0-2.0-0.6

-2.0-1.9-0.1-2.4+0.4

-1.8-1.0-0.8-1.2-0.6

-2.1-1.1-1.0-1.5-0.6

-4.1-0.6-3.5-1.7-2.5

15d

-5.1-3.0-2.1-4.3-0.9

-7.2-8.1+0.9-6.7-0.5

-16.0-4.8-11.2-5.1-10.9

-22.6-9.1-13.4-8.9-13.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco's September 2025 quarter standalone revenue rose 8.8% to Rs 429.3 crore, with profit of Rs 15.1 crore versus Rs 12.8 crore a year earlier. Consolidated quarterly loss narrowed to Rs 9.2 crore, but the half-year loss widened to Rs 45.6 crore. No qualification was reported, but FPP Holding and Warren Remedies had negative net worth of Rs 35.1 crore and Rs 50.9 crore.

Likely market impact

Revenue growth and a standalone profit are positive, but consolidated losses and uncertainty around two subsidiaries may weigh on the stock.